1223573-53-2

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate is used as a potential building block for the synthesis of new pharmaceutical compounds due to its unique spirocyclic structure. Its incorporation into drug molecules could potentially enhance their efficacy, selectivity, or stability, contributing to the advancement of novel therapeutic agents.
Used in Materials Science:
In the field of materials science, tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate is used as a component in the development of new materials with specific properties. Its unique structure may contribute to the creation of materials with tailored characteristics, such as improved mechanical strength, thermal stability, or chemical resistance.
However, it is important to note that further research is required to fully explore the potential uses and properties of tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate, as its current applications are speculative based on its structural features.

Upstream product

• 1223573-24-7 tert-butyl 3-(2-hydroxyethyl)-3-mercaptoazetidine-1-carboxylate 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 1223573-23-6 tert-butyl 3-(2-oxomethylene)azetidine-1-carboxylic acid 
• 1223573-52-1 tert-butyl 3-(acetylsulfanyl)-3-(2-oxoethyl)azetidine-1-carboxylate 

Downstream Products

• 1223573-25-8 tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate 1,1-dioxide 
• 1352546-75-8 1-thia-6-azaspiro[3.3]heptane-1,1-dioxide 
• 1427358-97-1 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide hydrochloric acid salt 

Relevant academic research and scientific papers

TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS

Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.

SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, R5, R6, W, and A are defined herein.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

Synthesis and structural analysis of a new class of azaspiro[3.3]heptanes as building blocks for medicinal chemistry

Figure presented Straightforward access toward previously unreported substituted, heterocyclic spiro[3.3]heptanes is disclosed. These spirocyclic systems may be considered as alternatives to 1,3-heteroatom-substituted cyclohexanes, which are otherwise insufficiently stable to allow their use in drug discovery. Conformational details are discussed on the basis of X-ray crystallographic structures.